This caveat notwithstanding, our results might offer an explanation to the reactivation of JCPyV replication that can be observed in NTZ-treated patients with MS, and suggest that miR-126-3p, POU2AF1, and Spi-B could be useful biomarkers to monitor JCPyV reactivation. Here, SPIB is linked to myeloid sarcoma.